- Lobbying
- braeburn
Lobbying Arrangements Results for 'Braeburn'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Orphan Drug Act reform |
Braeburn Pharmaceuticals
|
HCM Strategists | |||
Details HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act... |
Braeburn Inc. formerly known as Braeburn Pharmaceuticals Inc
|
in-house lobbying | |||
Details General issues related to the opioid crisis. |
Braeburn
|
Cove Strategies | |||
Details DEA IFR Issues - 14-day rule and Fairness in Orphan Drug Exclusivity Act |
Braeburn Inc.
|
PYXIS PARTNERS, LLC | |||
Details Opioid Use Disorder (OUD). |
Braeburn Pharmaceuticals
|
DA VINCI GROUP | |||
Details Advocacy regarding rules for market entry and prescription delivery. |
Braeburn Inc.
|
APCO Worldwide LLC | |||
Details Controlled Substances Act provisions relating to the distribution of medication assisted therapies (The Protecting Patient Access to Emergency Medications Act, S. 916/H.R. 304. Adequacy of funding... |
Braeburn Pharmaceuticals, Inc.
|
Knight Capitol Consultants | |||
Details Assisting in the resolution of Drug Enforcement Administrations rules around the provision of injectable buprenorphine addressed in S 916 Protecting Patient Access to Emergency Medications Act of 2... |
Braeburn Inc.
|
Waxman Strategies | |||
Details Legislative issues related to the treatment of opioid addiction and medicated assisted therapy |
Braeburn Pharmaceuticals, Inc.
|
Dentons US LLP | |||
Details Reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity ... |
Braeburn Pharmaceuticals, Inc.
|
STANTON PARK GROUP |